by Mark Chiang

马克·蒋

Share To

分享到

A recent evaluation of lecanemab, an Alzheimer’s treatment approved by the Food and Drug Administration in 2023, indicates that the drug has been well tolerated outside of clinical trial settings. Lecanemab gained attention for its ability to modestly slow disease progression, marking a significant milestone as the first medication capable of influencing Alzheimer’s disease.

最近对2023年美国食品药品监督管理局批准的阿尔茨海默病治疗药物Lecanemab的评估表明，该药物在临床试验环境之外也具有良好的耐受性。Lecanemab因其能够适度延缓疾病进展而备受关注，成为第一种能够影响阿尔茨海默病进程的药物，标志着一个重要的里程碑。

However, concerns arose during clinical trials regarding potential side effects, including brain swelling and bleeding, which led to hesitation among some patients and healthcare providers..

然而，在临床试验期间，人们对于潜在的副作用（包括脑肿胀和出血）产生了担忧，这导致一些患者和医疗保健提供者感到犹豫。

The findings suggest that these adverse effects may be less prevalent or manageable in real-world applications compared to controlled trial environments. The approval of lecanemab was initially met with optimism within the medical community due to its groundbreaking approach to addressing Alzheimer’s disease progression.

研究结果表明，与对照试验环境相比，这些不良反应在实际应用中可能较少发生或较易管理。Lecanemab 的批准最初因其在应对阿尔茨海默病进展方面的开创性方法而受到医学界的乐观看待。

Despite this enthusiasm, safety concerns highlighted during trials prompted caution among stakeholders. The latest observations provide additional insights into how the therapy performs beyond clinical settings, offering valuable information for physicians and patients considering its use..

尽管如此，试验期间凸显的安全性问题促使利益相关者保持谨慎。最新的观察结果提供了更多关于这种疗法在临床环境之外表现的见解，为考虑使用该疗法的医生和患者提供了有价值的信息。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: May 14, 2025

日期：2025年5月14日

Related posts:

相关文章:

Pharmaceutical Industry Turns to Data-Driven Strategies and AI to Strengthen Generic Drug Supply Chain.

制药行业转向数据驱动战略和人工智能以加强仿制药供应链。

CDMO Contracts: Clear Project Goals and IP Protection are Essential for Pharmaceutical Companies to Mitigate Project Failure Risks.

CDMO合同：明确的项目目标和知识产权保护对于制药公司降低项目失败风险至关重要。

Q&A: Scientist explains how she created ‘invisible’ stem cells

问与答：科学家解释她如何创造出“隐形”干细胞

Midlife Reflections Lead to Greater Happiness and Fulfillment

中年反思带来更大的幸福与满足

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

Mark Chiang

蒋志光

Related Post

相关文章

News Flash

新闻快讯

FDA Developing AI Tool Elsa to Streamline Pharmaceutical Application Reviews

FDA正在开发人工智能工具Elsa以简化药品申请审查流程

2025-06-09

2025年6月9日